207 Acute Incidence of Disease at Elevated Levels of Fine Particulate Matter (PM2.5) in Dublin, Ireland

ConclusionControls need to be brought in to ensure that PM2.5 does not exceed a 50μg/m3 level due to the increase in disease incidence associated with same. The urban burning of solid fuels should be severely restricted.
Source: Age and Ageing - Category: Geriatrics Source Type: research

Related Links:

Conclusions: In the context of high judicialization, patients suffering from PD must increasingly use the judicial system to access treatment. To promote more equitable and efficient access benefit packages, developing countries must consider more thoroughly the needs of these patients. PMID: 31627711 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Is there an association between personality and dementia risk? New research suggests traits such as vigor, calm, and maturity going as far back as high school may have a protective effect.Medscape Medical News
Source: Medscape Pediatrics Headlines - Category: Pediatrics Tags: Psychiatry News Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: Available online 20 October 2019Source: The LancetAuthor(s): Daniel I Sessler, Lijian Pei, Yuguang Huang, Edith Fleischmann, Peter Marhofer, Andrea Kurz, Douglas B Mayers, Tanja A Meyer-Treschan, Martin Grady, Ern Yu Tan, Sabry Ayad, Edward J Mascha, Donal J Buggy, Gang Tan, Zhiyong Zhang, Helen Keane, Maurice Stokes, Oliver Zotti, Michael Gnant, Silvia Perez-ProttoSummaryBackgroundThree perioperative factors impair host defence against recurrence during cancer surgery: the surgical stress response, use of volatile anaesthetic, and opioids for analgesia. All factors are ameliorated by regional anaesthesia...
Source: The Lancet - Category: General Medicine Source Type: research
CONCLUSIONS: Overall, hypothermia offers clinical benefit, most likely through its effects on the inflammatory response.
Source: Clinics - Category: General Medicine Source Type: research
The Food and Drug Administration approved AstraZeneca's drug Farxiga as a treatment for reducing the risk of hospitalizations for heart failure in adults with type-2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Farxiga, developed by AstraZeneca (NYSE: AZN) in a partnership with Bristol-Myers Squibb, already had FDA approval as a therapy along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug generated sales of more than…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
ConclusionA considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 20 October 2019Source: American Heart JournalAuthor(s): Neha J. Pagidipati, Yinggan Zheng, Jennifer B. Green, Darren K. McGuire, Robert J. Mentz, Svati Shah, Pablo Aschner, Tuncay Delibasi, Helena W. Rodbard, Cynthia M. Westerhout, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study GroupAbstractBackgroundObesity is a risk factor for type 2 diabetes (T2D) and cardiovascular disease (CVD). Whether obesity affects outcomes among those with T2D and atherosclerotic CVD (ASCVD) remains uncertain. Our objective was to investigate the relationship between body mass index (BMI) and ASC...
Source: American Heart Journal - Category: Cardiology Source Type: research
ConclusionsIn this observational analysis of T2D and ASCVD, baseline beta-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic beta-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205).
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Asthma | Atrial Fibrillation | Cardiology | Chronic Obstructive Pulmonary | Dementia | Environmental Health | Geriatrics | Heart | Heart Attack | Heart Failure | Ireland Health | Ischemic Stroke | Parkinson's Disease | Stroke | Study | UK Health